Valuation: Halozyme Therapeutics, Inc.

Capitalization 7.42B 7.06B 6.66B 5.88B 10.51B 642B 11.66B 79.29B 29.37B 269B 27.8B 27.24B 1,128B P/E ratio 2024 *
17.2x
P/E ratio 2025 * 12.9x
Enterprise value 8.4B 7.99B 7.54B 6.66B 11.9B 727B 13.2B 89.76B 33.26B 304B 31.47B 30.84B 1,277B EV / Sales 2024 *
8.37x
EV / Sales 2025 * 7.25x
Free-Float
98.92%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-0.55%
1 week+2.08%
Current month+2.91%
1 month+8.29%
3 months+8.02%
6 months+1.53%
Current year+21.92%
More quotes
1 week
56.51
Extreme 56.51
59.40
1 month
54.64
Extreme 54.64
59.40
Current year
47.52
Extreme 47.52
59.40
1 year
35.44
Extreme 35.44
65.53
3 years
29.85
Extreme 29.85
65.53
5 years
12.71
Extreme 12.71
65.53
10 years
6.96
Extreme 6.96
65.53
More quotes
Director TitleAgeSince
Chief Executive Officer 62 2014-01-05
Director of Finance/CFO 42 2022-02-01
Chief Operating Officer - -
Manager TitleAgeSince
Chairman 71 2006-07-30
Director/Board Member 57 2013-03-27
Director/Board Member 62 2014-01-05
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
-0.55%+2.08%+66.26%+73.28% 7.46B
-0.66%-2.93%-11.66%-22.72% 62.19B
-1.92%-2.41%-25.68%-28.46% 7.21B
+0.80%-1.26%+44.47%+57.93% 6.8B
-1.26%-8.59%+98.11%+139.99% 6.51B
+0.06%-12.06%+22.01%-11.53% 2.98B
-1.06%+1.85%+41.91%+29.63% 2.18B
+0.79%-1.79%+30.95%+27.48% 2.11B
+0.89%+1.56%-36.51%+48.31% 1.74B
-.--%-.--% - - 1.64B
Average -0.29%-2.65%+25.54%+34.88% 10.08B
Weighted average by Cap. -0.60%-3.03%+6.89%+4.09%
See all sector performances

Financials

2024 *2025 *
Net sales 1B 955M 901M 796M 1.42B 86.91B 1.58B 10.73B 3.97B 36.34B 3.76B 3.68B 153B 1.18B 1.13B 1.06B 939M 1.68B 103B 1.86B 12.66B 4.69B 42.9B 4.44B 4.35B 180B
Net income 438M 417M 393M 347M 620M 37.94B 689M 4.68B 1.73B 15.86B 1.64B 1.61B 66.59B 579M 551M 519M 459M 820M 50.12B 910M 6.19B 2.29B 20.96B 2.17B 2.13B 87.98B
Net Debt 980M 933M 880M 777M 1.39B 84.9B 1.54B 10.48B 3.88B 35.5B 3.67B 3.6B 149B 1.17B 1.11B 1.05B 925M 1.65B 101B 1.83B 12.46B 4.62B 42.23B 4.37B 4.28B 177B
More financial data * Estimated data
Logo Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.
Employees
373
Calendar
More about the company
Date Price Change Volume
25-02-14 58.29 $ -0.55% 1,000,607
25-02-13 58.61 $ +0.86% 883,155
25-02-12 58.11 $ +1.36% 888,174
25-02-11 57.33 $ -0.02% 1,143,602
25-02-10 57.34 $ +0.42% 967,321

Delayed Quote Nasdaq, February 14, 2025 at 04:00 pm

More quotes
Trading Rating
Investor Rating
ESG MSCI
BBB
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
58.29USD
Average target price
65.00USD
Spread / Average Target
+11.51%
Consensus

Quarterly revenue - Rate of surprise